Contact Us

New Product: Approval Granted for Beilu Pharmaceutical's Enteric-coated Prolonged-release Paroxetine Hydrochloride Tablets


Recently, Beilu Pharmaceutical received a Drug Registration Certificate from the National Medical Products Administration for Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets with a specification of 25mg (calculated as C₁₉H₂₀FNO₃).

Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets are used for the treatment of depression in adults and are listed in the national medical insurance catalog as category B, developed by GlaxoSmithKline. According to WHO data, over 350 million people worldwide suffer from depression, with an increase in patients of about 18% over the past decade, meaning that every year 5% of the global adult population is affected by depression. According to the 2022 National Depression Blue Book, there are about 95 million people suffering from depression in our country, representing a vast population. In the future, given the rise in the incidence rate of depression in our country and the increase in patient awareness, the market demand for this product is expected to grow further.

The approval of Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets as a Category 4 chemical drug, considered equivalent to passing the quality and efficacy consistency evaluation for generic drugs, will further enrich the company's psychoneurotic product line and help enhance the market competitiveness of the company's products. The company will actively carry out various preparations for the launch of the new product and aim to bring the product to market as soon as possible.

Related Products
Related News